Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S394000, C548S304400, C548S302100
Reexamination Certificate
active
10868090
ABSTRACT:
A compound of formula (I) or a salt thereof, or a solvate thereof, wherein: X represents oxygen, sulphur, or NRb; Y and Z each independently represent nitrogen, CH, CR1or CR2; A represents an unsubstituted or substituted aryl group or an unsubstituted or substituted heterocyclyl group; Rarepresents —C(O)NRsRt; R1and R2each independently represents hydrogen or specific substituents; and the use of such a compound in the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals.
REFERENCES:
patent: 4093726 (1978-06-01), Winn et al.
patent: WO 95/30659 (1995-11-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 98/01436 (1998-01-01), None
patent: WO 99/33822 (1999-07-01), None
Novelli, et al., “Synthesis and Biological Investigations of 2-(Tetrahydropyran-2′-yl) and 2-(Tetrahydrofuran-2′-yl)Benzimidazoles”, (1997), II Farmaco, 52(8-9), pp. 499-507.
Tsukamoto, et al., “Synthesis and Antiinflammatory Activity of Some 2-(Substituted-pyridnyl)benzimidazoles”, (1980), J. Med. Chem., 23, pp. 734-738.
Barraclough, et al., “Intropic 2-arylimidazol[1,2-a]pyrimidines”, (1992), Eur. J. Med. Chem., 27, pp. 207-217.
King, et al., “Synthesis and Thermal Reactions of 1,2-Dihydro-1,2,4-benzotriazines”, (1998), J. Chem. Soc., Perkins Trans 1 No 12 pp 3381-3385.
Piguet, et al., “Synthesis of Segmental Heteroleptic Ligands for the Self-Assembly of Heteronuclear Helical Supramolecular Complexes”, (1994), Helvetica Chimica Acta, vol. 77, pp. 931-942.
Database Crossfire 'Online!, Beilstein Institit zur Foerderung der Chemischen Wissenchaften, (XP002149940), Beilstein Registry No. 5988985 and 6009580 & Heterocycles, vol. 21, No. 6, (1985) pp. 1425-1430.
Database Crossfire 'Online!, Beilstein Institut zur Foerderung der Chemischen Wissenchaften, (XP002149941), Beilstein Registry No. 208984, 208985, 223809 and 298960 & Hel. Chim. acta, vol. 4 1921, pp. 428, 429, 436.
Database Crossfire 'Online!, Beilstein Institut zur Foerderung der Chemischen Wissenchaften, (XP002149942), Beilstein Registry No. 42810 and 25529 & G;as/ Je/ Dris/ Bepgrad. vol. 21, 1956, pp. 95, 98.
Database Crossfire 'Online!, Beilstein Institut zur Foerderung der Chemischen Wissenchaften, (XP002149943), Beilstein Registry No. 6003643 and J. Prakt. Chem., vol. 331, No. 4, 1989, pp. 649-658.
Farina, et al., “Selective inhibitors of vacuolar H+ -ATPase of osteoclasts with bone antiresorptive activity”, (1999), Expert Opinion on Therapeutic Patents, vol. 9, No. 2, pp. 157-168.
Vasikaran et al., Bisphosphonates: an overview with special reference to alendronate. Ann. Clin. Biochem. 38: 608-623, 2001.
Farina Carlo
Gagliardi Stefania
Rahman Shahzad Sharooq
Nikem Research S.R.L.
Saeed Kamal A.
LandOfFree
Azolylbenzamides and analogues and their use for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azolylbenzamides and analogues and their use for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azolylbenzamides and analogues and their use for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3722575